Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Solventum (SOLV) reported earnings 30 days ago. What's next for the stock?
SOLV - Solventum Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$91.22
DETAILS
HIGH:
$113.00
LOW:
$43.00
MEDIAN:
$95.00
CONSENSUS:
$91.22
DOWNSIDE:
0.51%
Stock News
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Solventum Corporation (NYSE:SOLV) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of Solventum Corporation (NYSE: SOLV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SOLV Plans Health Information Systems Business Spinoff to Drive Growth
Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.
SOLV Energy Q2 Earnings Call Highlights
SOLV Energy NASDAQ: MWH reported record first-half results for 2026, citing increased new-construction activity, project execution and contributions from prior acquisitions. The company also raised its full-year revenue and adjusted EBITDA outlook while reporting a 44% year-over-year increase in backlog.
SOLV Energy, Inc. (MWH) Q2 2026 Earnings Call Transcript
SOLV Energy, Inc. (MWH) Q2 2026 Earnings Call Transcript
SOLV Energy Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced financial results for the second quarter ended June 30, 2026. Financial Summary (in $ millions except percentages) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenue 951 536 1,628 944 Gross Profit 1 140 113 259 172 Gross Margin 1 14.7% 21.1% 15.9% 18.2% Net Income 2 67 45 39 44 Adjusted Gross Profit 3 145 113 269 172 Adjusted Gross Margin 3 15.2% 21.1% 16.5% 18.2% Adjusted EBITDA 117 86 210 120 Adjusted EBITDA Margin 12.4% 16.1% 12.9% 12.7% 1) Beginning with the second quarter of 2026, the Company classified certain annual incentive compensation within Cost of Revenue instead of Selling, general & administrative expense.
Here's Why Solventum (SOLV) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bank of America Corp DE Acquires 9,083 Shares of Solventum Corporation $SOLV
Bank of America Corp DE boosted its holdings in Solventum Corporation (NYSE: SOLV) by 0.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,432,780 shares of the company's stock after purchasing an additional 9,083 shares during the period. Bank
Solventum Q2 Earnings Call Highlights
Solventum NYSE: SOLV reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS, business as part of a broader effort to sharpen its focus on medical technology markets.
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
Solventum Corp (SOLV) (Q2 2026) Earnings Call Highlights: Strong Growth and Strategic Separation of HIS Business
Sales: $2.2 billion, up 9.5% organically and 2.2% on a reported basis.Normalized Organic Growth: Approximately 4%, excluding ERP advanced orders and other items
Solventum Corporation (SOLV) Q2 2026 Earnings Call Transcript
Solventum Corporation (SOLV) Q2 2026 Earnings Call Transcript
Solventum (SOLV) Q2 Earnings and Revenues Top Estimates
Solventum (SOLV) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.69 per share a year ago.
Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Solventum to hive off healthcare software business, raises profit forecast
Solventum , one of the largest providers of hospital consumables and sterilization devices, said on Wednesday it is planning to separate its health information systems business as part of its ongoing turnaround strategy.
Solventum Reports Second Quarter 2026 Financial Results
Reported sales increased 2.2%; organic sales increased 9.5% Announces intent to separate its Health Information Systems business segment Increases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow EAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.
Price Targets
Solventum price target raised to $100 from $90 at Stifel
$100.00
(was $84.82)
Stifel Nicolaus
Solventum price target raised to $101 from $95 at UBS
$101.00
(was $87.47)
Patrick Wood
·
UBS
Solventum price target raised to $113 from $100 at Mizuho
$113.00
(was $87.47)
Mizuho Securities
Solventum price target raised to $102 from $93 at KeyBanc
$102.00
(was $87.47)
KeyBanc
Solventum price target raised to $95 from $91 at BTIG
$95.00
(was $87.47)
Ryan Zimmerman
·
BTIG
Solventum assumed with Buy from Neutral at UBS
$95.00
(was $80.47)
UBS
Solventum price target raised to $91 from $89 at BTIG
$91.00
(was $76.70)
BTIG
BMO Capital starts Solventum at Market Perform amid 'many execution hurdles'
$81.00
(was $75.18)
BMO Capital
SOLV Energy Inc (MWH) PT Raised to $43 at JefferiesMember Login
$43.00
(was $74.95)
Jefferies
Solventum initiated with an Outperform at Wedbush
$94.00
(was $74.42)
Michael Piccolo
·
Wedbush
Solventum price target lowered to $78 from $82 at UBS
$78.00
(was $71.36)
Kevin Caliendo
·
UBS
Solventum price target lowered to $90 from $105 at Stifel
$90.00
(was $69.04)
Stifel Nicolaus
Solventum price target raised to $93 from $92 at KeyBanc
$93.00
(was $69.04)
Brett Fishbin
·
KeyBanc
Solventum price target lowered to $92 from $99 at KeyBanc
$92.00
(was $68.52)
Brett Fishbin
·
KeyBanc
Solventum price target lowered to $92 from $98 at Piper Sandler
$92.00
(was $68.88)
Piper Sandler
Solventum upgraded to Overweight from Sector Weight at KeyBanc
$97.00
(was $78.91)
Brett Fishbin
·
KeyBanc
Solventum upgraded to Outperform from Neutral at Mizuho
$100.00
(was $79.48)
Mizuho Securities
Solventum price target raised to $105 from $88 at Stifel
$105.00
(was $83.16)
Stifel Nicolaus
BTIG upgrades Solventum to Buy on better setup in 2026
$100.00
(was $85.56)
Ryan Zimmerman
·
BTIG
Solventum initiated with a Neutral at UBS
$77.00
(was $73.00)
Kevin Caliendo
·
UBS